Product Data Sheet

Brilliant Violet 510[™] anti-human CD49d

Catalog # / Size:	2121590 / 100 tests 2121585 / 25 tests	Δ
Clone:	9F10	
Isotype:	Mouse IgG1, κ	ž / /
Reactivity:	Human	f_{10}^{10}
Preparation:	The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 510 [™] under optimal conditions. The solution is free of unconjugated Brilliant Violet 510 [™] and unconjugated antibody.	
Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).	
Workshop Number:	V S215	
Concentration:	Lot-specific	

Applications:

Applications:	Flow Cytometry	
Recommended Usage:	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.	
	Brilliant Violet 510 [™] excites at 405 nm and emits at 510 nm. The bandpass filter 510/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 510 [™] is a trademark of Sirigen Group Ltd.	
	This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.	
Application Notes:	Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections, and <i>in vitro</i> T cell costimulation ^{2,3} . The LEAF TM Purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 304310).	
Application References:	1. Schlossman S, <i>et al.</i> Eds. 1995. Leucocyte Typing V. Oxford University Press. New York. 2. Jeong SH, <i>et al.</i> 2004. <i>J. Virol.</i> 78:6995. (Costim) 3. Vogel TU, <i>et al.</i> 2002. <i>J. Immunol.</i> 169:4511. (Costim)	

For research use only. Not for diagnostic use. Not for resale. Sony Biotechnology Inc. will not be held responsible for patent infringement or other violations that may occur with the use of our products. Sony Biotechnology Inc. 1730 North First Street, San Jose, CA 95112 www.sonybiotechnology.com 4. Kleinewietfeld M, et al. 2009. Blood 113:827. (FC) PubMed

- 5. Palacious F, *et al.* 2010. *Blood* 115:4488. <u>PubMed</u>
- 6. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
- 7. Sestak K, et al. 2007. Vet. Immunol. Immunopathol. 119:21.
- 8. Mattapallil MJ, et al. 2011. J. Immunol. 187:1977. PubMed

Description: CD49d is a 150 kD α integrin chain known as α_4 integrin or VLA-4 α chain. It forms a heterodimer with either integrin β_1 ($\alpha_4\beta_1$, VLA-4) or β_7 ($\alpha_4\beta_7$). CD49d is expressed broadly on T lymphocytes, B lymphocytes, monocytes, thymocytes, eosinophils, basophils, mast cells, NK cells, dendritic cells, and some non-hematopoietic cells, but not on normal red blood cells, platelets or neutrophils. VLA-4 binds to VCAM-1 (CD106) and fibronectin. $\alpha_4\beta_7$ is the receptor for VCAM-1 and MAdCAM-1. CD49d participates in mononuclear cell trafficking to endothelial sites of inflammation and has roles in cell-cell interactions and cell adhesion to extracellular matrices. CD49d is involved in lymphocyte migration, T cell activation, and hematopoietic stem cell differentiation. CD49d is a marker to isolate pure populations of Treg cells due to its absence on Foxp3⁺ cells.

Antigen1. Elices M, Ed.1995. Springer Semin. Immunopathol. 16(4).References:2. Lobb RR and Helmer ME. et al. 1994. J. Clin. Invest. 94:1722.